HIMSS26: Verily and Samsung Partner to Integrate Galaxy Watch 8 Into Precision Health Platform

Why It Matters

By turning a consumer‑grade smartwatch into a clinical data engine, the alliance removes a major bottleneck in trial recruitment and data integration, giving sponsors faster, higher‑quality evidence for drug development and public‑health research.

Key Takeaways

• Verily and Samsung integrate Galaxy Watch 8 into PRE platform.
• FDA‑cleared sleep apnea and AFib monitoring become clinical data sources.
• Continuous sensor data feeds directly into Verily’s Viewpoint Evidence.
• Refinery harmonizes wearable data with EHRs and surveys.
• Sponsors gain longitudinal, consented participant datasets for trials.

Pulse Analysis

The convergence of consumer wearables and clinical research has long been hampered by fragmented data pipelines rather than hardware limitations. Samsung’s Galaxy Watch 8, equipped with FDA‑cleared sleep‑apnea assessment and irregular heart rhythm detection, offers a robust sensor suite that meets regulatory standards while remaining comfortable for everyday use. This hardware credibility lays the groundwork for large‑scale, real‑world data collection without the logistical overhead of traditional medical devices.

Verily’s PRE platform adds the missing software layer, ingesting raw smartwatch streams into its Viewpoint Evidence ecosystem. Through the Refinery tool, disparate data types—continuous biometric readings, electronic health records, and patient‑reported outcomes—are normalized into a unified schema. The Workbench then applies AI and machine‑learning models to uncover patterns, predict outcomes, and generate actionable insights. By automating what was previously a manual, silo‑prone process, the partnership dramatically shortens the time from data capture to analysis.

For pharmaceutical companies and government agencies, the combined solution translates into faster trial enrollment, richer longitudinal cohorts, and more precise endpoint measurement. Participants benefit from a familiar device, improving adherence and reducing dropout rates. As the industry seeks to lower development costs and accelerate time‑to‑market, the Verily‑Samsung integration positions both firms at the forefront of a new era where consumer electronics serve as trusted clinical instruments, reshaping how health data fuels innovation.